Evidence map›Paper›PMID 34436607›Full record

ArticleJAMA network open2021

Complexity of Medication Regimens for Children With Neurological Impairment.

James A Feinstein, Hannah Friedman, Lucas E Orth, Chris Feudtner, Allison Kempe, Sadaf Samay, Allison B Blackmer

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03849066 completednot on this map

Enhancing Medication Safety in Children With Polypharmacy Using Parent- Reported Symptom Assessments

TypeobservationalSponsorUniversity of Colorado, DenverRan2019 to 2022Enrolled136ConditionsNeurologic Disorder, Chronic Disease, Pediatric DisorderArmsParent-Reported Symptom Assessment
NCT05761847 narecruitingnot on this mapstarted 2023, after this paper: background citation

Optimizing the Clinical Management of Polypharmacy for Children With Medical Complexity: The Pediatric Medication Therapy Management (pMTM) Trial

TypeinterventionalSponsorUniversity of Colorado, DenverRan2023 to 2028Enrolled371ConditionsChild, Only, Disabilities Multiple, Medication Interaction, Medication ComplianceArmsPediatric Medication Therapy Management (pMTM)
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Characterization of Treatment Utilization in a Metabolic Genetics Clinic.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  5. Article
  6. Article
  7. Medication Management Through Collaborative Practice for Children With Medical Complexity: A Prospective Case Series.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Effect of Pharmacy Involvement in Transitions of Care for Children With Medical Complexity.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

James A FeinsteinAdult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado and Children's Hospital Colorado, Aurora.
Hannah FriedmanPediatric Residency Program, University of Colorado, Aurora.
Lucas E OrthSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora.
Chris FeudtnerDivision of General Pediatrics, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Allison KempeAdult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado and Children's Hospital Colorado, Aurora.
Sadaf SamayResearch Informatics, Analytics Resource Center, Children's Hospital Colorado, Aurora.
Allison B BlackmerSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora.
University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · USChildren's Hospital Colorado · USChildren's Hospital of Philadelphia · US

Funding

Enhancing Medication Safety in Children with Polypharmacy Using Parent-Reported Symptom AssessmentsK23HD091295 · NICHD · UNIVERSITY OF COLORADO DENVER · PI FEINSTEIN, JAMES A · 2017 to 2021
$826k
NICHD NIH HHS K23 HD091295
6 · The paper itself

Abstract

Importance: Parents of children with severe neurological impairment (SNI) manage complex medication regimens (CMRs) at home, and clinicians can help support parents and simplify CMRs. Objective: To measure the complexity and potentially modifiable aspects of CMRs using the Medication Regimen Complexity Index (MRCI) and to examine the association between MRCI scores and subsequent acute visits. Design, Setting, and Participants: This cross-sectional study was conducted between April 1, 2019, and December 31, 2020, at a single-center, large, hospital-based, complex care clinic. Participants were children with SNI aged 1 to 18 years and 5 or more prescribed medications. Exposure: Home medication regimen complexity was assessed using MRCI scores. The total MRCI score is composed of 3 subscores (dosage form, dose frequency, and specialized instructions). Main Outcomes and Measures: Patient-level counts of subscore characteristics and additional safety variables (total doses per day, high-alert medications, and potential drug-drug interactions) were analyzed by MRCI score groups (low, medium, and high score tertiles). Associations between MRCI score groups and acute visits were tested using Poisson regression, adjusted for age, complex chronic conditions, and recent health care use. Results: Of 123 patients, 73 (59.3%) were male with a median (interquartile range [IQR]) age of 9 (5-13) years. The median (IQR) MRCI scores were 46 (35-61 [range, 8-139]) overall, 29 (24-35) for the low MRCI group, 46 (42-50) for the medium MRCI group, and 69 (61-78) for the high MRCI group. The median (IQR) counts for the subscores were 6 (4-7) dosage forms per patient, 7 (5-9) dose frequencies per patient, and 5 (4-8) instructions per patient, with counts increasing significantly across higher MRCI groups. Similar trends occurred for total daily doses (median [IQR], 31 [20-45] doses), high-alert medications (median [IQR], 3 [1-5] medications), and potential drug-drug interactions (median [IQR], 3 [0-6] interactions). Incidence rate ratios of 30-day acute visits were 1.26 times greater (95% CI, 0.57-2.78) in the medium MRCI group vs the low MRCI group and 2.42 times greater (95% CI, 1.10-5.35) in the high MRCI group vs the low MRCI group. Conclusions and Relevance: Higher MRCI scores were associated with multiple dose frequencies, complicated by different dosage forms and instructions, and associated with subsequent acute visits. These findings suggest that clinical interventions to manage CMRs could target various aspects of these regimens, such as the simplification of dosing schedules.

Indexed as

Drug Administration ScheduleDrug MonitoringAdolescentChildChild, PreschoolChronic DiseaseCross-Sectional StudiesFemaleHumansInfantMaleNervous System DiseasesUnited States

Identifiers

PMID34436607
PMCPMC8391103
OpenAlexW3193683785

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.